Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITPR3 | Q14573 | 8/20 | 1.00 |
| ▸ | ITPR2 | Q14571 | 4/20 | 1.00 |
| ▸ | ITPR1 | Q14643 | 4/20 | 1.00 |
| ▸ | INPP5A | Q14642 | 2/20 | 0.84 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.75 |
| ▸ | AKT1 | P31749 | 1/20 | 0.75 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9091859 | 1.00 | ITPR3 (1.00) | ITPR3ITPR2ITPR1INPP5AINPPL1 | |
| SCHEMBL9093199 | 1.00 | ITPR3 (1.00) | ITPR3ITPR2ITPR1INPP5AINPPL1 | |
| SCHEMBL9094714 | 1.00 | ITPR3 (1.00) | ITPR3ITPR2ITPR1INPP5AINPPL1 | |
| SCHEMBL8994052 | 1.00 | ITPR3 (1.00) | ITPR3ITPR2ITPR1INPP5AINPPL1 | |
| SCHEMBL9091912 | 1.00 | ITPR3 (1.00) | ITPR3ITPR2ITPR1INPP5AINPPL1 | |
| SCHEMBL405897 | 1.00 | ITPR3 (1.00) | ITPR3ITPR2ITPR1INPP5AINPPL1 | |
| SCHEMBL8775574 | 1.00 | ITPR3 (1.00) | ITPR3ITPR2ITPR1INPP5AINPPL1 | |
| SCHEMBL2044892 | 1.00 | ITPR3 (1.00) | ITPR3ITPR2ITPR1INPP5AINPPL1 | |
| SCHEMBL9387601 | 1.00 | ITPR3 (1.00) | ITPR3ITPR2ITPR1INPP5AINPPL1 | |
| SCHEMBL15067019 | 1.00 | ITPR3 (1.00) | ITPR3ITPR2ITPR1INPP5AINPPL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240181062-A1 | RED-SHIFTED PHOTOLIPIDS AND NANOPARTICLES FORMED FROM SAME | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2024-06-06 | — | — | US | claimed |
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20240181062-A1 | RED-SHIFTED PHOTOLIPIDS AND NANOPARTICLES FORMED FROM SAME | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2024-06-06 | — | — | US | disclosed |
| WO-2023220387-A2 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| EP-3131543-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF LIPID STORAGE DISORDERS | Neurotrope Bioscience (US) | 2017-02-22 | — | — | EP | disclosed |
| WO-2015160851-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF LIPID STORAGE DISORDERS | NEUROTROPE BIOSCIENCE (US) | 2015-10-22 | — | — | WO | disclosed |
| US-20140309186-A1 | Metabolomics-Based Identification of Disease-Causing Agents | GEORGIA TECH RESEARCH CORPORATION | 2014-10-16 | — | — | US | disclosed |
| US-20110246081-A1 | Metabolomics-Based Identification of Disease-Causing Agents | GEORGIA TECH RESEARCH CORPORATION (US) | 2011-10-06 | — | — | US | disclosed |
| WO-2009052186-A1 | METABOLOMICS-BASED IDENTIFICATION OF DISEASE-CAUSING AGENTS | GEORGIA TECH RESEARCH CORPORATION (US) | 2009-04-23 | — | — | WO | disclosed |
| US-20050148042-A1 | Hybrid phosphoinositide phospholipids: compositions and uses | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-07-07 | — | — | US | disclosed |
| US-6384260-B1 | ANALOGUES OF PHOSPHATIDYLINOSITOL-PHOSPHATES SUCH AS 1D-3,6-DI-O-BENZYL-MYO-INOSITOL AS RESEARCH REAGENTS, STRUCTURE- AND MECHANISM-BASED COMPETITIVE INHIBITORS; REPORTER OR ANCHORING GROUPS; CHEMICAL INTERMEDIATES | NUTRIMED BIOTECH | 2002-05-07 | — | — | US | disclosed |
| US-6232486-B1 | PHOSPHATIDYLINOSITOL PHOSPHATE | NUTRIMED BIOTECH | 2001-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | APOB, APOL1, LDLR | ITPR3 4386/4885ITPR2 4181/4885ITPR1 4140/4885 |
| US-20240181062-A1 | RED-SHIFTED PHOTOLIPIDS AND NANOPARTICLES FORMED FROM SAME | PLTP, SGMS2, PHOSPHO1 | ITPR3 1153/4885ITPR2 807/4885ITPR1 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.